Literature DB >> 29732153

Long-term disease free survival of gastric mixed adenoneuroendocrine carcinoma treated with multimodality therapy: A case report.

Guangjian Yang1, Dan Li2, Fangchao Zheng3, Lin Yang1.   

Abstract

Gastric mixed adenoneuroendocrine carcinoma, a rare malignant type of stomach tumor, is composed of components of adenocarcinoma and neuroendocrine tumor. This type of neoplasm usually has a poor prognosis since both components are malignant. A 65-year-old male presented with norexia, epigastric distention, abdominal and lumbar pain. Contrast computed tomography scan of the abdomen verified multiple lesions merged into a large mass. Histolopathological examination of the specimen from digestive endoscopy was verified to be gastric mixed adenoneuroendocrine carcinoma. The patient received a multimodality treatment of chemotherapy, surgical resection with radiotherapy and still remains alive with no evidence of metastasis or recurrence for over 5 years. The authors suggest that multimodality therapy may be beneficial and necessary to effictively treat mixed adenoneuroendocrine carcinoma.

Entities:  

Keywords:  MANEC; adenoneuroendocrine carcinoma; gastric cancer; long-term disease free survival; multimodality therapy

Year:  2018        PMID: 29732153      PMCID: PMC5920656          DOI: 10.3892/mco.2018.1594

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  11 in total

Review 1.  Small cell carcinomas of the gastrointestinal tract: clinicopathological features and treatment approach.

Authors:  Baruch Brenner; Laura H Tang; Jinruh Shia; David S Klimstra; David P Kelsen
Journal:  Semin Oncol       Date:  2007-02       Impact factor: 4.929

2.  Mixed adenoneuroendocrine carcinoma of gastrointestinal tract: report of two cases.

Authors:  Simona Gurzu; Zoltan Kadar; Tivadar Bara; Tivadar Bara; Adrian Tamasi; Leonard Azamfirei; Ioan Jung
Journal:  World J Gastroenterol       Date:  2015-01-28       Impact factor: 5.742

3.  Long-term results of surgery for small intestinal neuroendocrine tumors at a tertiary referral center.

Authors:  Olov Norlén; Peter Stålberg; Kjell Öberg; John Eriksson; Jakob Hedberg; Ola Hessman; Eva Tiensuu Janson; Per Hellman; Göran Åkerström
Journal:  World J Surg       Date:  2012-06       Impact factor: 3.352

4.  Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer.

Authors:  Nasser Hanna; Paul A Bunn; Corey Langer; Lawrence Einhorn; Troy Guthrie; Thaddeus Beck; Rafat Ansari; Peter Ellis; Michael Byrne; Mark Morrison; Subramanian Hariharan; Benjamin Wang; Alan Sandler
Journal:  J Clin Oncol       Date:  2006-05-01       Impact factor: 44.544

5.  Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms.

Authors:  C G Moertel; L K Kvols; M J O'Connell; J Rubin
Journal:  Cancer       Date:  1991-07-15       Impact factor: 6.860

Review 6.  Unusual case of small cell gastric carcinoma: case report and literature review.

Authors:  David Richards; Daniel Davis; Peisha Yan; Sushovan Guha
Journal:  Dig Dis Sci       Date:  2010-09-18       Impact factor: 3.199

7.  The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas.

Authors:  Jonathan R Strosberg; Domenico Coppola; David S Klimstra; Alexandria T Phan; Matthew H Kulke; Gregory A Wiseman; Larry K Kvols
Journal:  Pancreas       Date:  2010-08       Impact factor: 3.327

8.  Prognostic significance of neuroendocrine components in gastric carcinomas.

Authors:  Ji Y Park; Min-Hee Ryu; Young Soo Park; Hye Jin Park; Baek-Yeol Ryoo; Min Gyu Kim; Jeong Hwan Yook; Byung Sik Kim; Yoon-Koo Kang
Journal:  Eur J Cancer       Date:  2014-09-04       Impact factor: 9.162

Review 9.  Review article: the investigation and management of gastric neuroendocrine tumours.

Authors:  R Basuroy; R Srirajaskanthan; A Prachalias; A Quaglia; J K Ramage
Journal:  Aliment Pharmacol Ther       Date:  2014-03-13       Impact factor: 8.171

10.  Mixed adeno(neuro)endocrine carcinoma arising from the ectopic gastric mucosa of the upper thoracic esophagus.

Authors:  Toshihiro Kitajima; Sachiko Kaida; Seigi Lee; Shusuke Haruta; Hisashi Shinohara; Masaki Ueno; Koichi Suyama; Yasunori Oota; Takeshi Fujii; Harushi Udagawa
Journal:  World J Surg Oncol       Date:  2013-09-04       Impact factor: 2.754

View more
  3 in total

1.  Prognostic Threshold of Neuroendocrine Differentiation in Gastric Carcinoma: a Clinicopathological Study of 945 Cases.

Authors:  Yi Zou; Linying Chen; Xingfu Wang; Yupeng Chen; Liwen Hu; Saifan Zeng; Pengcheng Wang; Guoping Li; Ming Huang; Liting Wang; Shi He; Sanyan Li; Lihui Jian; Sheng Zhang
Journal:  J Gastric Cancer       Date:  2019-03-20       Impact factor: 3.720

2.  Pathologic Complete Response After Neoadjuvant Chemoradiation in a Patient with Gastric Neuroendocrine Cancer.

Authors:  Brady Laughlin; Aaron Scott; Uma Goyal
Journal:  Cureus       Date:  2019-07-23

Review 3.  Mixed Neuroendocrine Non-Neuroendocrine Neoplasms: A Systematic Review of a Controversial and Underestimated Diagnosis.

Authors:  Melissa Frizziero; Bipasha Chakrabarty; Bence Nagy; Angela Lamarca; Richard A Hubner; Juan W Valle; Mairéad G McNamara
Journal:  J Clin Med       Date:  2020-01-19       Impact factor: 4.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.